Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements for Zolpidem Based Prescription Sleep Aids

 Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements
      for Zolpidem Based Prescription Sleep Aids Administered at Bedtime

FDA-mandated zolpidem dosage reduction for bedtime products such as Ambien (5
mg and 10 mg tablets) and Ambien CR (6.25 mg and 12.5 mg tablets) does not
affect Intermezzo® (zolpidem tartrate 1.75 mg and 3.5 mg sublingual tablets)
C-IV dosing

Intermezzo is the first and only prescription sleep aid approved for use as
needed in the middle of the night when an awakening is followed by difficulty
returning to sleep when the patient has at least four hours of bedtime
remaining

PR Newswire

POINT RICHMOND, Calif., Jan. 10, 2013

POINT RICHMOND, Calif., Jan. 10, 2013 /PRNewswire/ --Transcept
Pharmaceuticals, Inc. (Nasdaq: TSPT) – The FDA is requiring that the
manufacturers of certain zolpidem based prescription sleep aids such as
Ambien® and Ambien CR®, and generic versions of these products, reduce the
recommended dose. FDA has informed the manufacturers of these products that
the recommended dose of zolpidem at bedtime for women should be lowered from
10 mg to 5 mg for immediate-release products such as Ambien, and from 12.5 mg
to 6.25 mg for extended-release products such as Ambien CR. FDA also informed
the manufacturers that, for men, the labeling should recommend that health
care professionals consider prescribing the lower doses―5 mg for
immediate-release products and 6.25 mg for extended-release products. The full
FDA announcement is available on the FDA website.
http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm

The FDA announcement further states, "The recommended doses of Intermezzo, a
lower dose zolpidem product approved for middle-of-the-night awakenings, are
not changing. At the time of Intermezzo's approval in November 2011, the label
already recommended a lower dosage for women than for men."

The FDA press release concludes, "To decrease the potential risk of impairment
with all insomnia drugs, health care professionals should prescribe, and
patients should take, the lowest dose capable of treating the patient's
insomnia. Patients who drive or whose activities require full alertness the
morning after use of an insomnia drug should discuss the appropriateness of
their medicine with their health professional."

"We are pleased that this action by FDA confirms the recommended dose of
Intermezzo at 3.5 mg in men and 1.75 mg in women for the treatment of insomnia
when a middle of the night awakening is followed by difficulty returning to
sleep, so long as they have at least 4 hours of remaining bedtime," stated
Glenn A. Oclassen, President and Chief Executive Officer of Transcept.

Intermezzo was developed by Transcept and is the Company's first FDA approved
product. Intermezzo is being marketed in the United States under the terms of
a collaboration agreement between Transcept and Purdue Pharmaceutical
Products, L.P.

Important Safety Information

Intermezzo is contraindicated in patients with known hypersensitivity to
zolpidem. Observed reactions with zolpidem include anaphylaxis and angioedema.

Co-administration with Intermezzo and other CNS depressants increases the risk
of CNS depression. Intermezzo should not be taken with alcohol. The use of
Intermezzo with other sedative-hypnotics (including other zolpidem products)
at bedtime or the middle of the night is not recommended.

The risk of next-day driving impairment (and psychomotor impairment) is
increased if Intermezzo is taken with less than four hours of bedtime
remaining; if a higher than recommended dose is taken; if co-administered with
other CNS depressants; or co-administered with other drugs that increase the
blood levels of zolpidem. A small negative effect on SDLP (standard deviation
of lateral position, a measure of driving impairment) may remain in some
patients four hours after the 1.75 mg dose in women, and after the 3.5 mg dose
in men, such that a potential negative effect on driving cannot be completely
excluded.

Additional Important Safety Information is presented below.

About Intermezzo

Intermezzo is the first and only prescription sleep aid approved for use as
needed for the treatment of insomnia when a middle-of-the-night awakening is
followed by difficulty returning to sleep. Intermezzo is not indicated for the
treatment of middle-of-the-night insomnia when the patient has fewer than four
hours of bedtime remaining before the planned time of waking. Intermezzo is
contraindicated in patients with known hypersensitivity to zolpidem. Observed
reactions with zolpidem include anaphylaxis and angioedema.

The safety and efficacy of Intermezzo was evaluated in two randomized,
double-blind, placebo-controlled studies in patients with insomnia
characterized by difficulty returning to sleep after a middle-of-the-night
awakening. Patients met the diagnosis for primary insomnia as defined by the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) and had at
least 3 prolonged middle-of-the-night awakenings per week of at least 30
minutes in duration.

In a four-week outpatient study in 295 adult patients aged 18 to 64 years (201
females, 94 males), Intermezzo 3.5 mg or placebo was taken on an as-needed
basis following spontaneous awakenings when patients had difficulty returning
to sleep after waking in the middle of the night, provided they had at least
four hours remaining in bed. Subjective time to fall back to sleep after a
middle-of-the-night awakening was significantly shorter for Intermezzo 3.5 mg
(38 minutes) compared to placebo (56 minutes).The most commonly observed
adverse reactions ( > 1% ) were headache (Intermezzo 3%, placebo 1%), nausea
(1% for both patient groups), and fatigue (Intermezzo 1%, placebo 0%).

In a sleep laboratory study, 82 adult patients aged 19 to 64 years (58
females, 24 males) were evaluated in a 3-period, 2-consecutive-night treatment
period cross-over design. Patients were awakened four hours after bedtime,
administered Intermezzo 3.5 mg, 1.75 mg, or placebo, and were kept awake for
30 minutes before lights-out. As compared to placebo, Intermezzo significantly
decreased objective mean time to fall back asleep after a middle-of-the-night
awakening (women taking 1.75 mg: 16 min vs. placebo: 28 min; men taking 3.5
mg: 13 min vs. placebo: 29 min).

How to Take Intermezzo

The recommended and maximum dose of Intermezzo for male adults is 3.5 mg and
for female adults is 1.75 mg, administered as a sublingual tablet only once
per night as needed if a middle-of-the-night awakening is followed by
difficulty returning to sleep. The recommended doses for men and women are
different because women clear zolpidem from the body at a lower rate than men.

The recommended dose for elderly men and women over 65 years old or patients
with hepatic impairment is 1.75 mg. The recommended dose for men and women who
are taking concomitant CNS depressants is 1.75 mg. Dose adjustment of
concomitant CNS depressants may be necessary when co-administered with
Intermezzo because of potentially additive effects. The use of Intermezzo with
other sedative-hypnotics (including other zolpidem products) at bedtime or the
middle of the night is not recommended.

Intermezzo is to be taken in bed when a patient wakes in the middle of the
night and has difficulty returning to sleep. Intermezzo should only be taken
if the patient has at least four hours of bedtime remaining before the planned
time of waking.

Intermezzo should be placed under the tongue and allowed to disintegrate
completely before swallowing. The tablet should not be swallowed whole. For
optimal effect, Intermezzo should not be administered with or immediately
after a meal. The blister should be removed from the pouch just prior to
dosing.

Each sublingual tablet is individually packaged in a foil blister inside a
unit-dose pouch. Before going to bed, a single pouch should be placed by the
bedside with a clock or watch nearby. All other unopened Intermezzo pouches
should be stored with other medicines away from the bedside. Patients should
open the Intermezzo pouch only when they are ready to use it.

Patients can either use the Dosing Time Chart or the Dosing Time Tool that
comes with Intermezzo to find the latest time during the night they can take
Intermezzo.

Dosing Time Tool: Patients turn a wheel to find the earliest time they must be
awake, which corresponds with instructions to take Intermezzo before a
specified time.

Dosing Time Chart: The chart helps patients locate the earliest time they need
to be awake and match it to the latest time they can take Intermezzo.

When patients wake in the morning, they should make sure that at least four
hours have passed since they took Intermezzo and they feel fully awake before
driving or engaging in other activities requiring full mental alertness.
Patients should not do dangerous activities until they know how Intermezzo
affects them.

Additional Important Safety Information

The failure of insomnia to remit after 7 to 10 days of treatment may indicate
the presence of a primary psychiatric and/or medical illness that should be
evaluated.

Cases of angioedema involving the tongue, glottis, or larynx have been
reported in patients after taking the first or subsequent doses of zolpidem.
Some patients have had additional symptoms such as dyspnea, throat closing, or
nausea and vomiting that suggest anaphylaxis. Some patients have required
medical therapy in the emergency department. Angioedema and additional
symptoms suggesting anaphylaxis may be fatal. Patients who develop angioedema
or anaphylaxis should not be re-challenged.

Abnormal thinking and behavior changes have been reported in patients treated
with a sedative-hypnotic, including zolpidem. Complex behaviors, including
driving or eating while not fully awake, with amnesia for the event, as well
as visual and auditory hallucinations and abnormal behaviors such as decreased
inhibition, bizarre behavior, agitation, and depersonalization may occur.
Although behaviors such as "sleep-driving" have occurred with zolpidem alone
at therapeutic doses, the co-administration of zolpidem with alcohol and other
CNS depressants increases the risk of such behaviors, as does the use of
zolpidem at doses exceeding the maximum recommended dose. Discontinuation of
Intermezzo should be strongly considered for patients reporting a
"sleep-driving" episode.

In primarily depressed patients, worsening of depression, including suicidal
thoughts and actions (including completed suicides) have been reported with
the use of sedative-hypnotics. Intentional overdosage is more common in this
group of patients; therefore, protective measures may be required. Prescribe
the least amount of Intermezzo that is feasible in these patients.

Because persons with a history of addiction to or abuse of drugs or alcohol
are at increased risk for misuse, abuse, and addiction of zolpidem, they
should be monitored carefully when receiving Intermezzo. Zolpidem tartrate is
a Schedule IV controlled substance. Post-marketing reports of abuse,
dependence, and withdrawal resulting from use of oral zolpidem tartrate have
been received. Zolpidem has produced withdrawal signs and symptoms following a
rapid dose decrease or abrupt discontinuation.

For additional information, please read the Intermezzo Full Prescribing
Information available at http://www.purduepharma.com/IntermezzoPI.

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Senior Director, Corporate Communications
(510) 215-3567
gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.

Website: http://www.transcept.com